Patrick Fratellone
Cardiovascular Disease · New York, NYNPI 1851347173
Payments from drug & device makers
Across 390 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Boehringer Ingelheim$862
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$759
- AbbVie$757
- Novo Nordisk$666
- Viiv Healthcare Company$481
- plus $3K from 26 others
What the payments were for
- Food & beverage$7,76299%
- Education$571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 66 | $1,264 |
| Boehringer Ingelheim | 52 | $862 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 38 | $759 |
| AbbVie | 37 | $757 |
| Novo Nordisk | 34 | $666 |
| Viiv Healthcare Company | 21 | $481 |
| Gilead | 15 | $460 |
| Lilly USA, LLC | 18 | $351 |
| IBSA Pharma Inc. | 18 | $331 |
| Johnson & Johnson(2 entities) | 15 | $304 |
| Akcea Therapeutics, Inc. | 8 | $229 |
| Pfizer | 9 | $172 |
| Vivus LLC | 7 | $145 |
| Amgen | 6 | $129 |
| E.r. Squibb & Sons, L.L.C. | 6 | $107 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $104 |
| Esperion Therapeutics, Inc. | 5 | $100 |
| Acella Pharmaceuticals, LLC | 4 | $85 |
| Antares Pharma, Inc. | 3 | $65 |
| Bayer | 3 | $59 |
| Jazz Pharmaceuticals Inc. | 2 | $49 |
| Avion Pharmaceuticals | 2 | $47 |
| Menarini Silicon Biosystems, Inc. | 2 | $47 |
| Currax Pharmaceuticals LLC | 3 | $43 |
| Phadia US Inc. | 2 | $34 |
| Azurity Pharmaceuticals, Inc. | 2 | $34 |
| Merck | 2 | $30 |
| Exact Sciences | 1 | $27 |
| Cleerly, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $18 |
| MDD US Operations, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Biktarvy$125
How this compares
$7,819 in reported general payments places this provider in the 75th percentile of 2,302 cardiovascular disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 15 | $14,021 |
| GlyxambiEmpagliflozin/Linagliptin | 15 | $11,660 |
| EliquisApixaban | 12 | $8,868 |
| Armour ThyroidThyroid,pork | 114 | $6,309 |
| PremarinEstrogens, Conjugated | 12 | $2,501 |
| SynthroidLevothyroxine Sodium | 36 | $2,200 |
| Liothyronine Sodium | 86 | $1,836 |
| Olmesartan Medoxomil | 26 | $1,283 |
| Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf) | 11 | $1,152 |
| Nebivolol Hcl | 11 | $852 |
| ValacyclovirValacyclovir Hcl | 20 | $777 |
| Amlodipine Besylate | 46 | $641 |
| Levothyroxine Sodium | 92 | $575 |
| Lorazepam | 13 | $410 |
| Metoprolol Succinate | 37 | $353 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus | $666 | $14,02115 claims |
| Boehringer IngelheimGlyxambi | $862 | $11,66015 claims |
| PfizerEliquis, Premarin | $172 | $11,36824 claims |
| AbbVieArmour Thyroid, Synthroid | $757 | $8,508150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in New York
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Gregg StoneNew York$3.7M
- Valentin FusterNew York$2.9M
- Tamim NazifNew York$2.2M
- Howard WeintraubNew York$1.7M
- Anuradha Lala-TrindadeNew York$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.